Evidence map›Paper›PMID 41631753›Full record

ArticleInvestigative ophthalmology & visual science2026

Theophylline Inhibits Capillary Degeneration in Early Diabetic Retinopathy.

Emma M Lessieur, Aicha Saadane, Yunpeng Du, Jianying Kiser, Alice Oum, Zak R Bollinger, Chieh A Lee, Jie Tang, Timothy S Kern

Abstract read
In one paragraph

Article in Investigative ophthalmology & visual science, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Emma M LessieurBrunson Center for Translational Vision Research, Gavin Herbert Eye Institute, University of California Irvine, Irvine, California, United States.
Aicha SaadaneBrunson Center for Translational Vision Research, Gavin Herbert Eye Institute, University of California Irvine, Irvine, California, United States.
Yunpeng DuBrunson Center for Translational Vision Research, Gavin Herbert Eye Institute, University of California Irvine, Irvine, California, United States.
Jianying KiserBrunson Center for Translational Vision Research, Gavin Herbert Eye Institute, University of California Irvine, Irvine, California, United States.
Alice OumBrunson Center for Translational Vision Research, Gavin Herbert Eye Institute, University of California Irvine, Irvine, California, United States.
Zak R BollingerBrunson Center for Translational Vision Research, Gavin Herbert Eye Institute, University of California Irvine, Irvine, California, United States.
Chieh A LeeDepartment of Ophthalmology, Case Western Reserve University, Cleveland, Ohio, United States.
Jie TangDepartment of Ophthalmology, Case Western Reserve University, Cleveland, Ohio, United States.
Timothy S KernBrunson Center for Translational Vision Research, Gavin Herbert Eye Institute, University of California Irvine, Irvine, California, United States.

Funding

Role of Photoreceptors in the Pathogenesis of Diabetic RetinopathyR01EY022938 · NEI · UNIVERSITY OF CALIFORNIA-IRVINE · PI KERN, TIMOTHY S · 2013 to 2021
$3.7M
Retina-derived extracellular vesicles in diabetic retinopathy: their potential role in pathogenesis and therapyR00EY034928 · NEI · DOHENY EYE INSTITUTE · PI Emma M Lessieur · 2025 to 2026
$494k
Retina-derived extracellular vesicles in diabetic retinopathy: their potential role in pathogenesis and therapyK99EY034928 · NEI · UNIVERSITY OF CALIFORNIA-IRVINE · PI LESSIEUR, EMMA M · 2023 to 2024
$215k
NEI NIH HHS K99 EY034928NEI NIH HHS R00 EY034928NEI NIH HHS R01 EY022938
6 · The paper itself

Abstract

Purpose: Recent evidence suggests that simultaneous inhibition of multiple diabetes-induced molecular abnormalities is a valuable approach toward inhibiting the development of early stages of diabetic retinopathy (DR). The methylxanthine, theophylline acts by multiple mechanisms in different diseases, and we investigated its effect on the development of lesions of early DR. Methods: Wild-type C57Bl/6J male mice were made diabetic with streptozotocin at two to three months of age, and some were given theophylline or structurally related analogs for one to two months to assess effects on visual function and biochemical and physiological abnormalities in the retina, or for eight months to assess retinal vascular histopathology. Effects of theophylline on leukocytes were examined ex vivo, because leukocytes contribute to the retinal vascular pathology of diabetes. Results: Retinal superoxide generation, expression of inflammatory proteins, leukocyte-mediated cytotoxicity against retinal endothelial cells, and degeneration of retinal capillaries were significantly increased in retinas of control diabetic mice, and theophylline inhibited each of these abnormalities. Of recognized actions of theophylline (adenosine receptor antagonist, antioxidant and anti-inflammatory agent, inducer of histone deacetylase activity, inhibitor of phosphodiesterases), the inhibition of phosphodiesterases, oxidative stress and inflammation seem most likely to account for the beneficial effects of the drug in DR. In contrast to the beneficial effect of theophylline on capillary degeneration, it did not inhibit the diabetes-induced dysfunction of the neural retina. Conclusions: Theophylline significantly inhibited the degeneration of retinal capillaries in early DR and can help investigate mechanistic differences in the pathogenesis of retinal capillary degeneration and neural dysfunction in diabetes.

Indexed as

Diabetes Mellitus, ExperimentalDiabetic RetinopathyRetinal DegenerationRetinal VesselsTheophyllineAnimalsCapillariesLeukocytesMaleMiceMice, Inbred C57BLOxidative StressSuperoxidesSuperoxidesTheophylline

Identifiers

PMID41631753
PMCPMC12882096

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.